强生2026Q3营收254亿美元超预期并上调全年指引，但调整后EPS同比降7.5%、利润率承压，股价盘中已跌约4.6%

S&P 500 dips marginally at the open, Nasdaq and Dow mixed after bank earnings
Introduction & Market Context
Johnson & Johnson (NYSE:JNJ) presented its third quarter 2026 earnings results on October 13, 2026, reporting sales of $25.4 billion and highlighting significant product innovations, though the company’s shares fell 4.36% to $252.24 as investors weighed margin pressure and mixed segment performance against the revenue beat.
The healthcare giant’s presentation emphasized its trajectory toward exceeding $100 billion in annual revenue for the first time in its 140-year history, driven by strong performance in Innovative Medicine offset by challenges in its MedTech division. The quarter included approximately $7 billion in special charges related to talc litigation and acquisitions, significantly impacting reported earnings.
Quarterly Performance Highlights
The company’s third quarter financial results showed worldwide sales of $25.4 billion, representing a 5.9% reported increase and 6.0% operational growth. However, adjusted diluted earnings per share of $2.59 declined 7.5% year-over-year, reflecting margin compression and increased investment spending.
As shown in the following summary of key financial metrics, the quarter demonstrated the divergence between top-line momentum and bottom-line pressure:
The presentation highlighted six key businesses driving operational growth: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. However, the 6.0% operational sales growth included an approximate 420 basis point headwind from Stelara, indicating underlying momentum was stronger than headline figures suggested.
CEO Joaquin Duato emphasized the company’s performance in prepared remarks: "Our strong third-quarter performance and increased sequential growth" alongside "transformative MedTech innovations with OTTAVA" and "positive Phase 3 results in multiple myeloma."
Regional Performance Analysis
Geographic results revealed significant variation in growth rates across markets, with U.S. performance substantially outpacing international regions. The following regional breakdown illustrates this divergence:
U.S. sales reached $15.0 billion, up 9.1% year-over-year, while international sales of $10.4 billion grew just 1.8% operationally. Europe showed flat reported growth at negative 0.6%, though operational growth was positive 1.0% when excluding currency impacts. The Western Hemisphere excluding the U.S. posted strong 12.5% reported growth, though operational growth was more modest at 8.0% due to currency effects.
Innovative Medicine Segment Strength
The Innovative Medicine division delivered $16.8 billion in sales, representing 7.9% operational growth despite a significant 690 basis point headwind from Stelara biosimilar competition. This performance was driven by strong execution across multiple therapeutic areas.
The company’s extensive portfolio strength is illustrated in its platform scale, with 16 Innovative Medicine products exceeding $1 billion in annual sales:
Oncology led segment growth with sales of $7.6 billion, up 16.7% operationally, driven by DARZALEX, CARVYKTI, TECVAYLI, and TALVEY gaining market share, along with launch uptake for RYBREVANT/LAZCLUZE combination therapy. The presentation detailed key product performance across therapeutic areas:
Immunology sales reached $4.2 billion, up 1.4% operationally, with TREMFYA showing strong share gains offset by STELARA’s decline from biosimilar competition and decreases in SIMPONI and REMICADE. The newer launches IMAAVY and ICOTYDE contributed growth from early uptake.
Neuroscience posted $2.4 billion in sales, up 17.6% operationally, with SPRAVATO benefiting from patient demand and CAPLYTA showing continued launch momentum. The INVEGA franchise increased from favorable patient mix despite share loss pressures.
MedTech Division Challenges
In contrast to Innovative Medicine’s strong performance, the MedTech segment delivered more modest results with $8.6 billion in sales and 2.5% operational growth. The company’s earnings call revealed management acknowledged this division underperformed internal expectations.
The segment breakdown revealed varied performance across categories:
Cardiovascular posted the strongest MedTech growth at 4.1% operationally, driven by Electrophysiology procedure growth and new products including VARIPULSE, TRUPULSE, and CRYSTAL platforms. However, Abiomed experienced declines from lower patient volumes, while Shockwave delivered double-digit growth from adoption of its Coronary and Peripheral portfolios.
Surgery sales declined 1.0% operationally, impacted by volume-based procurement in China, the company’s surgery transformation program, and Middle East disruptions. Within the category, Advanced Biosurgery grew approximately 3%, while Endocutters declined roughly 4%.
Vision grew 5.1% operationally, benefiting from the ACUVUE OASYS 1-Day family products and strategic pricing actions in Contact Lenses, along with demand for premium IOLs in Surgical Vision.
Orthopaedics increased 3.4% operationally, with growth from new products including the EMPHASYS hip system, the ATTUNE knee portfolio, and recently launched VOLT trauma products.
OTTAVA Robotic System Breakthrough
A major highlight of the quarter was the U.S. FDA market authorization for the OTTAVA Robotic Surgical System, which the company positioned as opening a new category in surgical robotics.
The breakthrough technology and its market potential are detailed in the following presentation slide:
The OTTAVA system represents the world’s first table-integrated soft tissue robotic system with four arms built into a standard surgical table. The De Novo authorization covers 10 general surgery procedures, including gastric bypass, gastric sleeve, cholecystectomy, and hiatal hernia repair.
The system’s competitive advantages include occupying 30-50% less space than traditional boom- and cart-mounted systems and connecting to the Polyphonic open digital ecosystem for data-driven insights. The company announced it has signed its first commercial customer and has an inguinal hernia trial in progress.
Financial Analysis and Margin Pressure
While revenue growth remained solid, the company faced significant margin compression during the quarter. Adjusted pre-tax operating margin decreased approximately 60 basis points compared to the prior year, an improvement from the 75 basis point decline previously guided but still representing meaningful pressure.
Research and development expenses increased 26.7% to $4.7 billion, or 18.3% of sales compared to 15.3% in the prior year, reflecting the company’s increased investment in pipeline development. The presentation highlighted $11.8 billion invested in R&D year-to-date.
Reported net earnings of $210 million, or $0.09 per diluted share, included approximately $7 billion in special items related to talc litigation resolution and acquisitions of Firefly Bio, Inc. and Sail Biomedicines. Adjusted net earnings of $6.3 billion, or $2.59 per diluted share, declined 6.8% from the prior year.
Capital Allocation Strategy
The company outlined its capital allocation priorities, emphasizing organic growth as the primary focus while maintaining flexibility for strategic investments:
Johnson & Johnson ended the quarter with $17 billion in cash and marketable securities against $45 billion in debt, resulting in net debt of $28 billion. Free cash flow reached approximately $15 billion for the first nine months, with full-year guidance of approximately $21 billion.
The company returned $3.2 billion to shareholders through dividends during the quarter, totaling $9.6 billion year-to-date. As a dividend aristocrat with 55 consecutive years of increases, Johnson & Johnson maintains its commitment to competitive shareholder returns while prioritizing investment in organic growth opportunities.
Updated Guidance and Outlook
Johnson & Johnson raised its full-year 2026 guidance, tightening ranges and increasing midpoints across key metrics. The updated outlook reflects confidence in the company’s trajectory toward the $100 billion revenue milestone:
The company now expects operational sales growth of 6.7% to 7.1%, with a midpoint of 6.9%, up from the previous 6.5% to 7.1% range. Reported sales guidance increased to $101.0 billion to $101.4 billion, representing 7.2% to 7.6% growth, with the midpoint rising by $0.1 billion.
Adjusted operational earnings per share guidance tightened to $10.95 to $11.05, representing 1.5% to 2.4% growth, with the midpoint increasing by $0.06 to 2.0%. Reported adjusted EPS guidance of $11.05 to $11.15 reflects 2.4% to 3.3% growth.
The company maintained its foreign exchange impact estimate of approximately $0.5 billion, or 0.5%, on sales and $0.10, or 0.9%, on adjusted EPS. The adjusted pre-tax operating margin decline improved to approximately 60 basis points from the previous 75 basis point guidance.
Strategic Initiatives and Pipeline
The presentation emphasized the breadth of Johnson & Johnson’s product portfolio and pipeline as drivers of long-term value creation. The company highlighted 29 platforms and products exceeding $1 billion in annual sales, split between 16 in Innovative Medicine and 13 in MedTech.
Key 2026 milestones driving long-term value creation span both business segments:
In Innovative Medicine, the company is advancing multiple programs including TECVAYLI and TALVEY in relapsed/refractory multiple myeloma, pasritamig and JNJ-6143 in prostate cancer, INLEXZO in high-risk non-muscle invasive bladder cancer, ICOTYDE in psoriatic arthritis, CAPLYTA in bipolar mania, TREMFYA in psoriatic arthritis structural damage, and nipocalimab in warm autoimmune hemolytic anemia and systemic lupus erythematosus.
MedTech milestones include the Dual Energy THERMOCOOL STSF catheter, C2 Aero Catheters, VARIPULSE Pro, OTTAVA robotic system, ETHICON 4000 stapler, TECNIS PureSee IOL, MONARCH Urology platform, and the VOLT suite of trauma products.
Management emphasized that the company’s double-digit growth target by the end of the decade is based on internal investment and pipeline execution rather than assumed mergers and acquisitions, though the company remains open to strategic opportunities.
Forward-Looking Perspective
Johnson & Johnson’s third quarter presentation portrayed a company navigating a period of transition, with strong momentum in Innovative Medicine offset by near-term challenges in MedTech and margin pressure from increased investment spending. The OTTAVA FDA authorization represents a potentially transformative development in the surgical robotics market, while the Innovative Medicine pipeline continues to advance multiple high-value assets.
The company’s path to exceeding $100 billion in annual revenue appears on track, though investors will be watching closely for evidence of MedTech improvement and margin stabilization in coming quarters. Management indicated it will provide more detailed guidance for 2027 and updates on the planned orthopedic business separation at an investor event scheduled for December 8, 2026.
The stock’s decline despite beating earnings expectations suggests investors are focusing on execution challenges and margin pressure rather than the positive revenue trajectory, reflecting concerns about whether the company can deliver sustainable profitable growth as it scales toward its long-term targets.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.